Analyst Craig Bijou of Bank of America Securities reiterated a Sell rating on Bausch + Lomb Corporation (BLCO – Research Report), reducing the price target to $17.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Craig Bijou has given his Sell rating due to a combination of factors including Bausch + Lomb Corporation’s recent performance and future projections. Although the company reported a solid fourth quarter with a 2% revenue beat and 10% organic growth driven by the product Miebo, the overall outlook was less optimistic. The 2025 EBITDA guidance fell short of investor expectations, signaling limited margin expansion and a lower-than-expected performance in the upcoming quarters.
Furthermore, the lack of acquisition opportunities for BLCO, following the announcement that a private equity buyout is unlikely, has contributed to a 10% decline in the stock price. This, combined with concerns about the company’s ability to separate from BHC and the minimal improvement in operating margins expected in the future, supports the decision to maintain a Sell rating. Though the pipeline shows potential with products like biomimetic contact lenses, the benefits are expected to take time to materialize.
Bijou covers the Healthcare sector, focusing on stocks such as Haemonetics, Integra Lifesciences, and Merit Medical Systems. According to TipRanks, Bijou has an average return of 2.2% and a 43.84% success rate on recommended stocks.